Products Categories
CAS No.: | 112885-42-4 |
---|---|
Name: | Mosapride citrate |
Article Data: | 7 |
Molecular Structure: | |
Formula: | C21H25ClFN3O3.C6H8O7 |
Molecular Weight: | 616.014 |
Synonyms: | Gasmotin;Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Benzamide,4-amino-5-chloro-2-ethoxy-N- [[4-[(4-fluorophenyl)methyl]-2-morpholinyl]- methyl]-,2-hydroxy-1,2,3-propanetricarboxylate (1:1);(+-)-4-Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate;Gasmotin (TN);4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; 2-hydroxypropane-1,2,3-tricarboxylic acid;AS 4370;(±)- 4 –Amino-5-chloro-2-ethoxy-N-((4-(4-fluorobenzyl)-2-morpholinyl)methyl)benzamide citrate dihydrate;4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-benzamide 2-hydroxy-1,2,3-propanetricarboxylate; |
EINECS: | 601-211-6 |
Melting Point: | 143-145° |
Boiling Point: | 549.2 °C at 760 mmHg |
Flash Point: | 286 °C |
Appearance: | white powder |
PSA: | 227.41000 |
LogP: | 2.62370 |
Conditions | Yield |
---|---|
In ethanol; water at 70 - 75℃; for 0.5h; Temperature; | 97.2% |
at 80 - 110℃; for 0.5h; Product distribution / selectivity; | 95.45% |
In ethanol; water at 50℃; for 1h; Solvent; Temperature; | 94.7% |
In ethanol; water at 20℃; for 2h; | 89% |
4-acetylamino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide
citric acid
mosapride citrate
Conditions | Yield |
---|---|
In methanol; water at 50 - 65℃; Temperature; | 88.7% |
Conditions | Yield |
---|---|
Stage #1: (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide dihydrochloride With sodium hydroxide In dichloromethane; water for 0.5h; Heating / reflux; Stage #2: citric acid In water at 0℃; for 0.5h; Heating / reflux; | 88% |
mosapride
mosapride citrate
Conditions | Yield |
---|---|
With citric acid In water at 0℃; Heating / reflux; | 86% |
(RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide trifluoroacetate
mosapride citrate
Conditions | Yield |
---|---|
Stage #1: (RS)-4-amino-5-chloro-2-ethoxy-N-{[4-(4-fluoro-benzyl)-2-morpholinyl]-methyl}-benzamide trifluoroacetate With sodium hydroxide In dichloromethane; water Stage #2: With citric acid In water | 83% |
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 2: methanol; water / 50 - 65 °C View Scheme |
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 2: methanol; water / 50 - 65 °C View Scheme |
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 2: methanol; water / 50 - 65 °C View Scheme |
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 2: methanol; water / 50 - 65 °C View Scheme |
sodium p-aminosalicylate
mosapride citrate
Conditions | Yield |
---|---|
Multi-step reaction with 5 steps 1: water / 4 h / 45 °C 2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C 3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C 4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 5: methanol; water / 50 - 65 °C View Scheme | |
Multi-step reaction with 5 steps 1: water / 4 h / 45 °C 2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C 3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C 4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 5: methanol; water / 50 - 65 °C View Scheme | |
Multi-step reaction with 5 steps 1: water / 4 h / 45 °C 2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C 3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C 4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 5: methanol; water / 50 - 65 °C View Scheme | |
Multi-step reaction with 5 steps 1: water / 4 h / 45 °C 2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C 3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C 4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 5: methanol; water / 50 - 65 °C View Scheme | |
Multi-step reaction with 5 steps 1: water / 4 h / 45 °C 2: potassium carbonate / N,N-dimethyl-formamide / 4 h / 20 °C 3: N-chloro-succinimide / N,N-dimethyl-formamide / 3 h / 80 °C 4: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; dmap; triethylamine / dichloromethane / 1 h / -10 - -5 °C 5: methanol; water / 50 - 65 °C View Scheme |
The CAS register number of Mosapride Citrate is 112885-42-4. It also can be called as Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and the IUPAC name about this chemical is 4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide; 2-hydroxypropane-1,2,3-tricarboxylic acid. The molecular formula about this chemical is C27H33ClFN3O10 and the molecular weight is 614.02. It belongs to the Gastroprokinetic Agent.
Physical properties about Mosapride Citrate are: (1)ACD/LogP: 2.82; (2)ACD/LogD (pH 5.5): 1.98; (3)ACD/LogD (pH 7.4): 2.79; (4)ACD/BCF (pH 5.5): 11.7; (5)ACD/BCF (pH 7.4): 76.6; (6)ACD/KOC (pH 5.5): 116.16; (7)ACD/KOC (pH 7.4): 760.78; (8)#H bond acceptors: 6; (9)#H bond donors: 3; (10)#Freely Rotating Bonds: 8; (11)Polar Surface Area: 45.25Å2; (12)Flash Point: 286 °C; (13)Enthalpy of Vaporization: 82.9 kJ/mol; (14)Boiling Point: 549.2 °C at 760 mmHg; (15)Vapour Pressure: 4.11E-12 mmHg at 25°C.
The Mosapride Citrate is used for functional dyspepsia with heartburn, belching, nausea, vomiting, early satiety, the abdominal distension, gastrointestinal symptoms such as upper abdominal pain. In addition, this chemical can also be used for gastroesophageal reflux disease, diabetic gastroparesis, and gastric resection in patients with dysfunction of the stomach.
You can still convert the following datas into molecular structure:
(1)SMILES: O=C(O)C(O)(CC(=O)O)CC(=O)O.Clc1cc(c(OCC)cc1N)C(=O)NCC3OCCN(Cc2ccc(F)cc2)C3
(2)InChI: InChI=1/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
(3)InChIKey: HUZTYZBFZKRPFG-UHFFFAOYAN
(4)Std. InChI: InChI=1S/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
(5)Std. InChIKey: HUZTYZBFZKRPFG-UHFFFAOYSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | > 400mg/kg (400mg/kg) | GASTROINTESTINAL: NAUSEA OR VOMITING | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
mouse | LD50 | intraperitoneal | 914mg/kg (914mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
mouse | LD50 | oral | > 3gm/kg (3000mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
mouse | LD50 | subcutaneous | > 1gm/kg (1000mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
rat | LD50 | intraperitoneal | > 1gm/kg (1000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LIVER: OTHER CHANGES | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
rat | LD50 | oral | > 3gm/kg (3000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |
rat | LD50 | subcutaneous | > 1gm/kg (1000mg/kg) | Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 21, Pg. 3343, 1993. |